Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246846 | 0.89 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL13248365 | 0.88 | MEN1 (0.56) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL2996834 | 0.85 | ADAMTS4 (0.46) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL13248366 | 0.85 | NPSR1 (0.45) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL2243764 | 0.85 | ALOX5AP (0.53) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL5198442 | 0.84 | MAOB (0.48) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL2246968 | 0.84 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL2246935 | 0.82 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL2248325 | 0.82 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL2248075 | 0.81 | ALOX5AP (0.39) | SMN1; SMN2PARP10CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190346-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-04 | — | — | US | claimed |
| EP-1814877-B1 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIBITORS | MERCK & CO INC (US) | 2009-03-11 | — | — | EP | claimed |
| EP-1814877-A2 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIBITORS | Merck & Co., Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006044602-A9 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIIBITORS | MERCK & CO INC (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006044602-A2 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIIBITORS | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-8729104-B2 | Diphenyl substituted alkanes as flap inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20110190346-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-1814877-B1 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIBITORS | MERCK & CO INC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. | 2007-12-13 | — | — | US | disclosed |
| EP-1814877-A2 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIBITORS | Merck & Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006044602-A9 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIIBITORS | MERCK & CO INC (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006044602-A2 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIIBITORS | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190346-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | ALOX5, ALOX15, ALOX15B | NPC1 1072/4885RAB9A 4248/4885SMN1; SMN2 4311/4885 |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | ALOX5, ALOX15, ALOX15B | NPC1 1072/4885RAB9A 4248/4885SMN1; SMN2 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.